Monogram Announces Presentation Of Clinical Data For The HERmark(TM) Breast Cancer As

[News]

Monogram Biosciences, Inc. (Nasdaq: MGRM) announced that scientific collaborators have presented additional clinical results on HERmark(TM), the company's novel oncology assay, as a means to measure HER2 total protein and homodimer levels and predict response to Herceptin(R) (trastuzumab) in patients with metastatic breast cancer at the 44th ASCO Annual Meeting taking place in Chicago, Illinois.

More... (http://www.medicalnewstoday.com/articles/109602.php)